Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study.

Mankowski C, Poole CD, Ernault E, Thomas R, Berni E, Currie CJ, Treadwell C, Calvo JI, Plastira C, Zafeiropoulou E, Odeyemi I.

BMC Neurol. 2017 Apr 21;17(1):80. doi: 10.1186/s12883-017-0836-z.

2.

Cost-effectiveness and budget impact of Empirical vitamin D therapy on unintentional falls in older adults in the UK.

Poole CD, Smith J, Davies JS.

BMJ Open. 2015 Sep 29;5(9):e007910. doi: 10.1136/bmjopen-2015-007910.

3.

Can skin disease cause neuropathic pain? A study in pachyonychia congenita.

Wallis T, Poole CD, Hoggart B.

Clin Exp Dermatol. 2016 Jan;41(1):26-33. doi: 10.1111/ced.12723. Epub 2015 Sep 11.

PMID:
26358843
4.

Antibiotic treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis.

Currie CJ, Berni E, Jenkins-Jones S, Poole CD, Ouwens M, Driessen S, de Voogd H, Butler CC, Morgan CL.

BMJ. 2014 Sep 23;349:g5493. doi: 10.1136/bmj.g5493.

5.

Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs.

Emery P, Gallo G, Boyd H, Morgan CL, Currie CJ, Poole CD, Nab HW.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5):653-60. Epub 2014 Sep 5.

PMID:
25190189
6.

The medico-legal aspects of prescribing vitamin D.

Davies JS, Poole CD, Feldschreiber P.

Br J Clin Pharmacol. 2014 Dec;78(6):1257-63. doi: 10.1111/bcp.12472. Review.

7.

Vitamin D and falls.

Davies JS, Poole CD.

Lancet Diabetes Endocrinol. 2014 Jul;2(7):540-1. doi: 10.1016/S2213-8587(14)70125-1. No abstract available.

PMID:
24999259
9.

The short-term impact of vitamin D-based hip fracture prevention in older adults in the United Kingdom.

Poole CD, Smith JC, Davies JS.

J Endocrinol Invest. 2014 Sep;37(9):811-7. doi: 10.1007/s40618-014-0109-2. Epub 2014 Jun 24.

PMID:
24957166
10.

Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy.

Poole CD, Bannister CA, Andreasen JN, Andersen JS, Currie CJ.

Health Qual Life Outcomes. 2014 Jun 13;12:99. doi: 10.1186/1477-7525-12-99.

11.

Use of 5% lidocaine medicated plasters for the treatment of pain in routine hospital practice: patient reported pain, functioning and satisfaction.

Khot S, Morgan CL, Kadambande S, Poole CD.

Curr Med Res Opin. 2014 Aug;30(8):1573-8. doi: 10.1185/03007995.2014.915212. Epub 2014 May 12.

PMID:
24773481
12.

Vitamin D: too much of a good thing?

Davies JS, Poole CD.

Br J Gen Pract. 2014 Jan;64(618):8-9. doi: 10.3399/bjgp14X676276. No abstract available.

13.

The effect of withdrawal of rosiglitazone on treatment pathways, diabetes control and patient outcomes: a retrospective cohort study.

Morgan CL, Puelles J, Poole CD, Currie CJ.

J Diabetes Complications. 2014 May-Jun;28(3):360-4. doi: 10.1016/j.jdiacomp.2014.01.007. Epub 2014 Jan 17.

PMID:
24529918
14.

Primary prevention of diabetic retinopathy with fibrates: a retrospective, matched cohort study.

Morgan CL, Owens DR, Aubonnet P, Carr ES, Jenkins-Jones S, Poole CD, Currie CJ.

BMJ Open. 2013 Dec 3;3(12):e004025. doi: 10.1136/bmjopen-2013-004025.

15.

Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.

Morgan CL, Emery P, Porter D, Reynolds A, Young A, Boyd H, Poole CD, Currie CJ.

Rheumatology (Oxford). 2014 Jan;53(1):186-94. doi: 10.1093/rheumatology/ket333. Epub 2013 Oct 18.

PMID:
24140761
16.

The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010).

Holden SE, Jenkins-Jones S, Poole CD, Morgan CL, Coghill D, Currie CJ.

Child Adolesc Psychiatry Ment Health. 2013 Oct 11;7(1):34. doi: 10.1186/1753-2000-7-34.

17.

External validation of the UKPDS risk engine in incident type 2 diabetes: a need for new type 2 diabetes-specific risk equations.

Bannister CA, Poole CD, Jenkins-Jones S, Morgan CL, Elwyn G, Spasic I, Currie CJ.

Diabetes Care. 2014 Feb;37(2):537-45. doi: 10.2337/dc13-1159. Epub 2013 Oct 2.

PMID:
24089541
18.

The incidence of type 2 diabetes in the United Kingdom from 1991 to 2010.

Holden SH, Barnett AH, Peters JR, Jenkins-Jones S, Poole CD, Morgan CL, Currie CJ.

Diabetes Obes Metab. 2013 Sep;15(9):844-52. doi: 10.1111/dom.12123. Epub 2013 May 16.

PMID:
23675742
19.

Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes.

Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL.

J Clin Endocrinol Metab. 2013 Feb;98(2):668-77. doi: 10.1210/jc.2012-3042. Epub 2013 Jan 31.

20.

Omega-3 Fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction: a retrospective, matched-cohort study.

Poole CD, Halcox JP, Jenkins-Jones S, Carr ES, Schifflers MG, Ray KK, Currie CJ.

Clin Ther. 2013 Jan;35(1):40-51. doi: 10.1016/j.clinthera.2012.11.008. Epub 2012 Dec 13.

21.

The impact of treatment non-compliance on mortality in people with type 1 diabetes.

Currie CJ, Peyrot M, Morgan CL, Poole CD, Jenkins-Jones S, Rubin RR, Burton CM, Evans M.

J Diabetes Complications. 2013 May-Jun;27(3):219-23. doi: 10.1016/j.jdiacomp.2012.10.006. Epub 2012 Nov 13.

PMID:
23157988
22.

What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes.

Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ.

J Clin Endocrinol Metab. 2012 Dec;97(12):4605-12. doi: 10.1210/jc.2012-3034. Epub 2012 Oct 17.

PMID:
23076348
23.

The impact of treatment noncompliance on mortality in people with type 2 diabetes.

Currie CJ, Peyrot M, Morgan CL, Poole CD, Jenkins-Jones S, Rubin RR, Burton CM, Evans M.

Diabetes Care. 2012 Jun;35(6):1279-84. doi: 10.2337/dc11-1277. Epub 2012 Apr 17.

24.

Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival.

Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL.

Diabetes Care. 2012 Feb;35(2):299-304. doi: 10.2337/dc11-1313. Epub 2012 Jan 20.

25.

Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs.

Morgan CL, Jenkins-Jones S, Evans M, Barnett AH, Poole CD, Currie CJ.

Diabetes Obes Metab. 2012 May;14(5):424-32. doi: 10.1111/j.1463-1326.2011.01552.x. Epub 2012 Jan 17.

PMID:
22192841
26.

Deriving health state utilities for the numerical pain rating scale.

Dixon S, Poole CD, Odeyemi I, Retsa P, Chambers C, Currie CJ.

Health Qual Life Outcomes. 2011 Nov 3;9:96. doi: 10.1186/1477-7525-9-96.

27.

Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin.

Holden SE, Poole CD, Morgan CL, Currie CJ.

BMJ Open. 2011 Jan 1;1(2):e000258. doi: 10.1136/bmjopen-2011-000258.

28.

Clinical effectiveness of biphasic insulin aspart 30:70 versus biphasic human insulin 30 in UK general clinical practice: a retrospective database study.

Morgan CL, Evans M, Toft AD, Jenkins-Jones S, Poole CD, Currie CJ.

Clin Ther. 2011 Jan;33(1):27-35. doi: 10.1016/j.clinthera.2011.01.023. Erratum in: Clin Ther. 2011 Mar;33(3):391.

PMID:
21397771
29.

A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis.

Poole CD, Connolly MP, Nielsen SK, Currie CJ, Marteau P.

J Crohns Colitis. 2010 Sep;4(3):275-82. doi: 10.1016/j.crohns.2009.11.010. Epub 2009 Dec 10.

PMID:
21122516
30.

Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007*.

Currie CJ, Gale EA, Poole CD.

Diabet Med. 2010 Aug;27(8):938-48. doi: 10.1111/j.1464-5491.2010.03040.x.

PMID:
20653753
31.

Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK.

Poole CD, Lebmeier M, Ara R, Rafia R, Currie CJ.

Rheumatology (Oxford). 2010 Oct;49(10):1949-56. doi: 10.1093/rheumatology/keq182. Epub 2010 Jun 26.

PMID:
20581376
32.

Quality of life and health-related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids.

Poole CD, Chambers C, Allsopp R, Currie CJ.

J Eur Acad Dermatol Venereol. 2010 Jun;24(6):674-8. doi: 10.1111/j.1468-3083.2009.03485.x.

PMID:
20565562
33.

Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study.

Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, Zagar T, Poole CD.

Lancet. 2010 Feb 6;375(9713):481-9. doi: 10.1016/S0140-6736(09)61969-3. Epub 2010 Jan 26.

PMID:
20110121
34.

Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis.

Connolly MP, Poole CD, Currie CJ, Marteau P, Nielsen SK.

Digestion. 2009;80(4):241-6. doi: 10.1159/000235916. Epub 2009 Oct 15.

PMID:
19828955
35.

Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic CONTROL study.

Poole CD, Chambers C, Sidhu MK, Currie CJ.

Br J Dermatol. 2009 Dec;161(6):1335-40. doi: 10.1111/j.1365-2133.2009.09379.x. Epub 2009 Jul 1.

PMID:
19754867
36.

An overview and commentary on retrospective, continuous glucose monitoring for the optimisation of care for people with diabetes.

Currie CJ, Poole CD, Papo NL.

Curr Med Res Opin. 2009 Oct;25(10):2389-400. doi: 10.1185/03007990903094452. Review.

PMID:
19650750
37.

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.

Currie CJ, Poole CD, Gale EA.

Diabetologia. 2009 Sep;52(9):1766-77. doi: 10.1007/s00125-009-1440-6. Epub 2009 Jul 2.

PMID:
19572116
38.

An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial.

Connolly MP, Nielsen SK, Currie CJ, Poole CD, Travis SP.

J Crohns Colitis. 2009 Feb;3(1):32-7. doi: 10.1016/j.crohns.2008.10.004. Epub 2008 Dec 6.

PMID:
21172245
40.
41.

Potential flaws and biases in a randomized controlled trial (RCT) of insulin determir vs. insulin glargine by Pieber and colleagues.

Alcolado J, Poole CD, Peters JR, Currie CJ.

Diabet Med. 2008 Jan;25(1):115-6. doi: 10.1111/j.1464-5491.2007.02335.x. No abstract available.

PMID:
18199142
42.
43.

Ischaemic heart disease in men.

Currie CJ, Conway P, Poole CD.

Heart. 2007 Nov;93(11):1471; author reply 1471-2. No abstract available.

44.
45.
46.

The financial costs of healthcare treatment for people with Type 1 or Type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy.

Currie CJ, Poole CD, Woehl A, Morgan CL, Cawley S, Rousculp MD, Covington MT, Peters JR.

Diabet Med. 2007 Feb;24(2):187-94.

PMID:
17257282
47.

The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy.

Currie CJ, Poole CD, Woehl A, Morgan CL, Cawley S, Rousculp MD, Covington MT, Peters JR.

Diabetologia. 2006 Oct;49(10):2272-80. Epub 2006 Aug 30.

PMID:
16944094
48.

Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes.

Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P.

Curr Med Res Opin. 2006 Aug;22(8):1523-34.

PMID:
16870077
49.

The impact of the overactive bladder on health-related utility and quality of life.

Currie CJ, McEwan P, Poole CD, Odeyemi IA, Datta SN, Morgan CL.

BJU Int. 2006 Jun;97(6):1267-72.

50.

Something old, something new: facility expansion emphasizes holistic health.

Poole CD.

Health Facil Manage. 1995 Dec;8(12):14-5. No abstract available.

PMID:
10152919

Supplemental Content

Loading ...
Support Center